Correction: Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides

Correction: Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219840/?tool=EBI

Similar Items

Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
by: Yu-Li Lo, et al.
Published: (2014-01-01)

Correction: Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides.
Published: (2014-01-01)

Cytotoxicity and reversal effect of sertraline, fluoxetine, and citalopram on MRP1- and MRP7-mediated MDR
by: Yuval Bin Kanner, et al.
Published: (2023-11-01)

Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2
by: Maria Gagliardi, et al.
Published: (2022-01-01)

Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes
by: Kiyoko Setoguchi, et al.
Published: (2017-12-01)

MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
by: Mengyang Chang, et al.
Published: (2022-08-01)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
by: Mike-Andrew Westhoff, et al.
Published: (2022-01-01)

Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4
by: Hee-Jeong Lee, et al.
Published: (2022-04-01)

BCL-XL regulates the timing of mitotic apoptosis independently of BCL2 and MCL1 compensation
by: Chun Yin Yu, et al.
Published: (2024-01-01)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
by: D.S. Dalafave, et al.
Published: (2010-08-01)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
by: D.S. Dalafave, et al.
Published: (2010-01-01)

<it>Multidrug resistance-associated protein-1 (MRP1) </it>genetic variants, MRP1 protein levels and severity of COPD
by: Rutgers Bea, et al.
Published: (2010-05-01)

Role of MRP-1 and GST-Pi in MDR and their inhibition by indomethacin in AML
by: Samia A. Ebeed, et al.
Published: (2017-08-01)

Localization of the ATP-binding cassette (ABC) transport proteins PfMRP1, PfMRP2, and PfMDR5 at the <it>Plasmodium falciparum </it>plasma membrane
by: Luty Adrian JF, et al.
Published: (2009-08-01)

Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer
by: Dimitrios E. Magouliotis, et al.
Published: (2022-11-01)

MDR-1 and MRP2 gene polymorphisms in Mexican epileptic pediatric patients with complex partial seizures.
by: David eEscalante-Santiago, et al.
Published: (2014-10-01)

Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells
by: Riya Biswas, et al.
Published: (2019-09-01)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
by: Enyuan Shang, et al.
Published: (2018-10-01)

Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
by: Crown John, et al.
Published: (2009-06-01)

Advances in Bcl-xL Research 2.0
by: Joann Kervadec, et al.
Published: (2023-05-01)

Involvement of human and canine MRP1 and MRP4 in benzylpenicillin transport.
by: Xiaofen Zhao, et al.
Published: (2019-01-01)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
by: Enyuan Shang, et al.
Published: (2020-08-01)

Bioactive Compounds from Penicillium sp. Inhibit Antiapoptotic Bcl-2, Bcl-XL and Mcl-1: An in silico Study
by: Adhie Massardi, et al.
Published: (2023-07-01)

Bcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
by: Hanjie Yi, et al.
Published: (2020-06-01)

IN VIVO ENRICHMENT OF REGULATORY T CELLS BY BCL-2/BCL-XL INHIBITION PROMOTES TOLERANCE IN ALLOTRANSPLANTATION
by: Gabriel, S, et al.
Published: (2013)

Evaluation of bcl-2, bcl-xl and bax expression and apoptotic index in canine mammary tumours
by: YILDIRIM F, et al.
Published: (2014-07-01)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
by: Li Ji-Yu, et al.
Published: (2012-12-01)

In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotides
by: Marvin Rubenstein, et al.
Published: (2011-04-01)

MRP+ : the adaptation, enhancement, and application of MRP II /
by: 318305 Turbide, David A.
Published: (1993)

Transport Characteristics of Tryptanthrin and its Inhibitory Effect on P-gp and MRP2 in Caco-2 Cells
by: Xingang Zhu, et al.
Published: (2011-08-01)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
by: Katrine Melvold, et al.
Published: (2022-03-01)

UK-2A ANALOGUES: POTENTIAL INHIBITORS OF BCL-XL
by: , AMJ Putra, M Hanafi, Y Anita
Published: (2007)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
by: Reut Yosef, et al.
Published: (2016-04-01)

Bcl-xL in neuroprotection and plasticity
by: Elizabeth Ann Jonas, et al.
Published: (2014-09-01)

Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
by: Siti Fairus Abdul Rahman, et al.
Published: (2020-07-01)

FGF-2 inhibits TNF-α mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells
by: Hey-Ryun Kim, et al.
Published: (2012-05-01)

Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL
by: Digant Nayak, et al.
Published: (2024-03-01)

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
by: Yiru Zhang, et al.
Published: (2018-05-01)

Praf2 is a novel Bcl-xL/Bcl-2 interacting protein with the ability to modulate survival of cancer cells.
by: Maria Teresa Vento, et al.
Published: (2010-12-01)

MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma
by: Lin Shibo, et al.
Published: (2013-01-01)